In a recent conversation with Neurocenter Finland, our CEO Tuija Keinonen talks about welcoming new innovations and approaches in the future and making Finland an interesting destination for research. According to her, innovations give rise to further innovations, which can be validated efficiently to support drug development: to improve diagnosis, the use of drugs, therapeutic success, compliance, and quality of life.
In her interview, she discusses Medfiles’s business model which is based on transfer and sales of expertise and is a combination of Finnish excellence and know-how as well as solid experience that delivers high-quality service package to its customers. She further goes on explaining how Neurocenter Finland and Medfiles can benefit by collaborating and utilizing each other’s know-how as a sales and marketing tool consequently, making Finland a more interesting destination for researchers, clients, and investors.
Read the whole interview here!